Allergan Rejects Valeant Again

Jun 10 2014 | 12:00pm ET

Valeant Pharmaceuticals International’s $53 billion offer for Allergan Inc. is still not rich enough for the latter.

Valeant, which is working with Pershing Square Capital Management on the bid, increased the offer twice late last month. But Allergan, which has said it prefers to remain independent, isn’t budging.

“We do not believe your latest proposal offers sufficient or certain value to warrant discussions between Allergan and Valeant,” Allergan CEO David Pyott wrote to his counterpart at Valeant, Michael Pearson.

That is not likely to sit well with Pershing Square’s William Ackman, Allergan’s largest shareholder, who has championed a deal and insisted that Allergan hold talks with Valeant. This week, Ackman said he had the support of a number of large Allergan investors for a deal at $180 per share, roughly the value of Valeant’s latest bid.

Ackman is also preparing a proxy fight to oust a majority of Allergan’s board later this year. The Botox-maker said the board’s vote against Valeant’s most recent offer was unanimous.

Allergan has blasted Valeant as a serial acquirer whose strategy is unsustainable. Pyott wrote that the latest proposal both “substantially undervalues” his company and “creates significant risks and uncertainties.”


In Depth

Change In 'Accredited Investor' Definition Could Hurt Crowdfunding Space

Jul 25 2014 | 8:14am ET

The Securities and Exchange Commission is considering changes to its 30-year-old...

Lifestyle

David Yarrow On Growing His Hedge Fund And Shooting The Animals And People Of Africa - As A Photographer

Jul 23 2014 | 6:44am ET

While he’s always been a photographer, recent expeditions to Iceland, Ethiopia...

Guest Contributor

The Truth About Track Record Portability

Jul 24 2014 | 5:55am ET

The number of private funds converting to mutual funds has increased significantly...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Publisher's Note